News overview
News
16 September 2022
Highlights of the European Society of Medical Oncology Congress 2022 in Paris
Are you curious about the highlights of the European Society of Medical Oncology Congress 2022 in Paris? Oncode's Yuva Oz was there to report about all of the interesting and relevant data presented.
YuvaOz
<span>Yuva</span><span>Oz</span>
Over 17 years of experience in Molecular Biology, Yuva completed her MSc. degree at EMBL Heidelberg and conducted her PhD research on the topic of Chromatin and Biomedical Genetics at Hubrecht Institute as a Marie-Curie fellow. Interested in clinical aspects of the research, she joined to oncology specialized clinical research organization SMS-oncology, gaining experience both in clinical trial management (early phase paediatric and adult trials) and Business Development aspects. At Oncode, she is driving the industry engagement programme to enable new alliances and collaborations between Oncode and biopharma to fast-forward research and innovation. Furthermore, working closely with Oncode Investigators, she supports technology, clinical and IP assessments for efficiently translating fundamental research into clinical benefit. She is the founder and designer at Art 4 Science, a scientific visualization – graphic design company.
News
8 September 2022
4.UNCAN.eu is officially launching today!
Oncode is pleased to take part in the kick-off meeting of the CSA (Coordination and Support Action) for the 4.UNCAN.eu initiative, taking place today and tomorrow in Paris. Arising from the EU’s Mission on Cancer and Europe’s Beating Cancer plan, the initiative is focused on generating a research roadmap to better UNderstand poorly understood CANcers (UNCAN).
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
26 August 2022
Vacancy: (Senior) Stakeholder Engagement Manager
Are you looking for an exciting role where you can apply your strategic and communication skills in a dynamic, fast-paced work environment? Then you are in the right place! Oncode Institute is currently looking for a Stakeholder Engagement Manager who thrives at building new and existing relations with important stakeholders.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
19 August 2022
(Future) researchers and patients join forces to make true impact
For the second year in a row, Oncode’s Patient Engagement Programme had the opportunity to contribute to the bachelor course ‘Eye for Impact’ for biomedical sciences students at University Medical Center Utrecht (UMCU). A unique example of how to give substance to patient engagement in basic research. Oncode researchers and patient representatives participated in a series of lectures and interactive sessions, where the students experienced first-hand how patients and researchers can partner up.
News
10 August 2022
Unravelling genetic mechanism behind tumor formation can improve targeted treatment
New research by the group of Jos Jonkers explains variation in treatment response to FGFR2 inhibitors and provides a way to improve targeted therapy for cancer patients. Their work highlights the importance of analyzing the functional consequences of genetic variants found in tumors.
News
4 August 2022
Chemotherapy speeds up DNA-level aging
Chemotherapy is an important part of treatment for children with cancer, contributing to the recovery of more and more children. Childhood cancer survivors do sometimes experience late effects from their treatment, including a higher risk of developing a second cancer. That risk is very small, but about five to six times greater than in the ‘normal’ population. In new research, published in Cancer Discovery, the team of Oncode Investigator Ruben Van Boxtel (Princess Máxima Center) shows that accelerated DNA aging turns out to be the main cause of the harmful effect of chemotherapy treatment.
News
4 August 2022
Paving the way for targeted therapy development for peritoneal metastases in colorectal cancer
Many patients with colorectal cancer suffer from metastases in the abdominal cavity, which have a big impact on quality of life and lead to poor survival. The team of Oncode Investigator Louis Vermeulen and collaborators have now shown that peritoneal metastases occur almost exclusively in a particular type of colon cancer: CMS4. With their research, published in Nature Communications, the team is now able to explain why and how this type of colon cancer can metastasize to the peritoneum.
News
29 July 2022
A new European strategic initiative to better understand cancer: 4.UNCAN.eu is calling for experts!
4.UNCAN.eu is launching a “Call for Expert Working Groups” (EWGs). Scientific leaders with expertise in 6 different areas of cancer research will be invited to help identify the research priorities that need to be addressed to reach a new level of understanding in cancer. These research priorities are intended to serve as guidelines for the European Scientific Community (including the Cancer Mission Board) to set specific calls for funding, as well as use cases to feed a European Federated Cancer Research Data Hub.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
27 July 2022
Oncode Investigator Madelon Maurice receives KWF funding for innovative SureTAC technology
At the start of the year, Argobio and Oncode have teamed up with Oncode Investigator Madelon Maurice (UMCU) and launched Laigo Bio, a new spin-off from the University Medical Center Utrecht (UMCU) in the emerging field of targeted protein degradation. Now, KWF has announced that this public-private collaboration will receive 1.2 million euros subsidy from the PPP allowance that Health~Holland makes available to KWF from the top sector Life Sciences & Health (LSH).
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
26 July 2022
New research puts the mode-of-action of T-cell immunotherapies in focus
A new 3D imaging and analysis technique, developed in Oncode Investigator Anne Rios’ lab at the Princess Máxima Center , brings the working mode of T-cell immunotherapies into live view. Researchers plan to use the new imaging technique to improve T-cell therapies for solid tumors. The results of this collaborative research endeavor were published today in the leading journal Nature Biotechnology.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
14 July 2022
Looking towards the future, together
On July 4th and 5th, almost 400 Oncode researchers gathered in De Rijtuigenloods in Amersfoort, indulging themselves in hot-of-the-press science conducted by their colleagues. Participants had the opportunity to listen to more than 20 scientific talks, divided in six research subjects spanning all the Oncode research fields, gather around posters and discuss the latest findings – and, of course, enjoy each other’s company and do live networking over coffee and drinks.
News
13 July 2022
Exciting research from the Kops and van Rheenen labs now published in Nature
The research team of Oncode Investigator Geert Kops (Hubrecht Institute) reports that the 3D location of chromosomes in the interphase cell nucleus affects how likely they are to be incorrectly transmitted to daughter cells. The results of their study highlight yet another functional role of 3D genome organization in cells. Oncode Investigator Jacco van Rheenen (NKI) and his research team filmed stem cells in the colon and small intestine and found different levels of stem cell regulation, which has a major impact on the onset of cancer.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
Scroll for more